Navigation Links
HORIZONS AMI trial data will help set guidelines
Date:10/24/2007

WASHINGTON, DC OCTOBER 24, 2007 Late-breaking data presented at TCT 2007, the scientific symposium of the Cardiovascular Research Foundation (CRF), show that the use of the anticoagulant bivalirudin following angioplasty in heart attack patients reduces net adverse clinical events by 24 percent compared to the standard treatment, and significantly reduces major bleeding that occurs after angioplasty by 40 percent.

Results of the HORIZONS AMI trial, sponsored by the Cardiovascular Research Foundation, were measured at 30 days; the patients will be observed for five years to collect long-term data.

This is a landmark trial, which will help establish the guidelines for drug and stent therapy during primary angioplasty in patients with heart attacks for many years to come, said Gregg W. Stone, MD, Chairman of the Cardiovascular Research Foundation and Professor of Medicine, Columbia University Medical Center.

Usually, angioplasty is associated with an excess of bleeding in heart attack patients, Dr. Stone said. In the first phase of the HORIZONS AMI trial, we sought to determine whether using bivalirudin instead of heparin and glycoprotein IIb/IIIa inhibitors in patients with a heart attack after angioplasty reduces this high rate of bleeding and improves survival, as it does in stable coronary artery disease.

In addition, while previous studies of drug-eluting stents have often focused on their use in patients with stable or unstable chest pain, this is the largest study to focus on the appropriate use of anticoagulation medications and drug-eluting stents in patients experiencing the most dangerous form of heart attack (ST-elevation myocardial infarction).

The HORIZONS AMI trial enrolled over 3600 patients presenting to hospitals in 11 countries with a heart attack. More than 120 national and international interventional cardiology centers are participating in the trial. Patients undergoing angioplasty were randomly assigned to receive either the standard anticoagulant regimen of unfractionated heparin plus a glycoprotein IIb/IIIa inhibitor or bivalirudin alone. The patients are to be followed for five years.

At 30 days, net adverse clinical events a combination of major bleeding or major adverse cardiac event were 12.1% in patients receiving heparin and GP IIb/IIIa inhibitors, and 9.2% in patients receiving bivalirudin alone. And when considered by itself, major bleeding was 8.3% in patients on combination drug therapy, vs. 4.9% in patients on bivalirudin alone.

In an important finding, cardiac deaths at 30 days were significantly higher in patients on heparin and GP IIb/IIIa inhibitors (2.9%) than those on bivalirudin alone (1.8%). Other important endpoints, such as second heart attacks and strokes, occurred with nearly identical frequency with bivalirudin and standard therapy.

This study determines that bivalirudin use is safer than previous standard anticoagulant therapy, without causing excess bleeding in these acutely ill patients with a heart attack undergoing angioplasty, which may translate into lower mortality, said Roxana Mehran, MD, Medical Director of the Data Coordinating and Analysis Center at CRF stated. She and her team conducted this study under an Investigational Device Exemption (IDE) from the Food and Drug Administration.

Comparison of Drug-Eluting Stents to Bare-Metal Stents Underway

Patients enrolled in the HORIZONS AMI trial were also randomly assigned to receive either Taxus drug-eluting stents or a bare-metal stent. Data on this portion of the study also a landmark comparison of drug-eluting stents to bare-metal stents will be available next year.


'/>"/>

Contact: Irma Damhuis
idamhuis@crf.org
917-558-5180
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Man against HIV – new vaccine ready for human trials
2. FDA approves Phase 0 trial which tests experimental drugs on humans
3. Male contraceptive in trial
4. How do patients benefit of clinical trials
5. Glenmark’s new molecule to go through trial
6. Clinical trials need to be more frank
7. First head-to-head trials of once weekly Fosamax and Actonel therapies
8. Hormone Replacement Therapy increases the risk of endometrial cancer
9. Atrial fibrillation predicts for acute ischaemic stroke
10. Spray on contraceptive clears Phase I trial
11. The Indian Government has given the nod to conduct Human volunteer trials inorder to develop preventive AIDS vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 13, 2017 , ... As health professionals work to improve their approach to ... is doing more than filling out a survey; in many cases health professionals and ... in health care and research on the importance of active engagement with patients and ...
(Date:10/13/2017)... IL (PRWEB) , ... October 13, 2017 , ... ... which established the certification process to promote standards of excellence for the field ... Symposium, scheduled for March 22 – 25, 2018 in Orlando, Florida at the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Lori R. Somekh, ... member of ElderCounsel, a national organization of elder law and special needs planning attorneys. ... and rules. It also provides a forum to network with elder law attorneys nationwide,” ...
(Date:10/13/2017)... , ... October 13, 2017 , ... The Visiting Nurse ... Market. Featuring a collection of specialty vendors and unique items from across the nation, ... quality-focused health and wellness services offered by the VNA. The boutique will be ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released ... understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture ... Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that is ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans ... advance the use of wearable and home sensors for ... disorders. Early Signal Foundation, a nonprofit organization focused on ... will provide an affordable analytical system to record and ... ...
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
(Date:9/18/2017)... , Pa. and KALAMAZOO, Mich. , Sept. ... Penn. , and OptiMed Specialty Pharmacy of ... partnership to offer a strategic hub service that expedites ... highly sought-after personal spirometer, Spiro PD 2.0, and wellness ... A spirometer is a medical device used to measure ...
Breaking Medicine Technology: